These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17445479)

  • 1. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 2. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 3. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
    Saijo N
    Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
    [No Abstract]   [Full Text] [Related]  

  • 5. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
    Lara PN
    Clin Lung Cancer; 2006 Jan; 7(4):232-4. PubMed ID: 16512975
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 15. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Calvo E; Baselga J
    J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.
    Kani K; Sordella R; Mallick P
    Methods Mol Biol; 2012; 795():233-53. PubMed ID: 21960227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
    Wozniak AJ
    J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1084-5. PubMed ID: 19861927
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
    Del Re M; Vasile E; Falcone A; Danesi R; Petrini I
    Expert Rev Mol Diagn; 2014 May; 14(4):453-68. PubMed ID: 24725257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
    Bunn PA
    J Clin Oncol; 2007 Jun; 25(18):2504-5. PubMed ID: 17577025
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.